Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
about
Trial watch - inhibiting PARP enzymes for anticancer therapyChloroquine and hydroxychloroquine for cancer therapyEffect of oxaliplatin combined with polyenephosphatidylcholine on the proliferation of human gastric cancer SGC-7901 cellsForced expression of S100A10 reduces sensitivity to oxaliplatin in colorectal cancer cellsChemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer.Oxaliplatin-induced immune-mediated cytopenias: a case report and literature review.Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive suA phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer.Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study.Nanocarriers for delivery of platinum anticancer drugs.A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumorsOxaliplatin: a review in the era of molecularly targeted therapyPharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosisOxaliplatin and its enantiomer induce different condensation dynamics of single DNA moleculesOxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis.A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancerA novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma.Oxaliplatin in the treatment of colorectal cancer.Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat.Oxaliplatin-Induced Leukocytoclastic Vasculitis under Adjuvant Chemotherapy for Colorectal Cancer: Two Cases of a Rare Adverse Event.Colorectal cancer-targeted delivery of oxaliplatin via folic acid-grafted solid lipid nanoparticles: preparation, optimization, and in vitro evaluation.Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic review.Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min.Lactobionic acid coupled liposomes: an innovative strategy for targeting hepatocellular carcinoma.Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect.Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatinCell cycle arrest by oxaliplatin on cancer cells.Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma.Upregulation of CX3CL1 mediated by NF-κB activation in dorsal root ganglion contributes to peripheral sensitization and chronic pain induced by oxaliplatin administration.Rate and extent of oxaliplatin absorption after hyperthermic intraperitoneal administration in peritoneal carcinomatosis patients.MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA.[Raltitrexed and oxaliplatin in colorectal cancer: in vitro and in vivo study of a synergistic cytostatic combination].Effects of the compounds resveratrol, rutin, quercetin, and quercetin nanoemulsion on oxaliplatin-induced hepatotoxicity and neurotoxicity in mice.Safety and efficacy of calcium and magnesium infusions in the chemoprevention of oxaliplatin-induced sensory neuropathy in gastrointestinal cancers.Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery.Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity.Establishment, functional and genetic characterization of a colon derived large cell neuroendocrine carcinoma cell line
P2860
Q26745673-5DA47150-4A42-41E0-9EC9-5155629821EFQ26827797-ED95F347-35B3-412B-A184-542755E8A6BEQ28468621-B56ED138-4B78-42BB-973A-0A2E693D110DQ28659746-D22749F0-F4DB-4CAE-9694-646653C66BC4Q33340282-4820B794-98A2-4BC0-985F-7539C0156486Q33344682-554DA1E1-C3AB-448E-BBDF-38974F1ACD15Q33400095-94EED601-E2E5-4161-BA6C-1C5D34601BC8Q33413179-4221391C-B51F-43F1-B73B-A6A1B23FBAF1Q33416659-94A0EA7A-11AA-4296-A7D8-D60F29451960Q33651496-FBBE22D5-B8DE-4062-AE9F-664725026EDCQ33653575-079747E5-1548-4E6F-B8C8-A90626EFFD51Q34338695-71E52504-5BF2-4C5F-9F64-25926573B076Q34352278-33C7F785-4D4F-4AF7-8E49-A080069C0295Q34541434-FC79EB39-D199-4DCD-A11F-B81A7BED8C9BQ34544598-322DD8D5-9002-47F9-90DE-7C3DDF9772DFQ34949875-51A02DD1-891C-449C-A68F-D3E15E5C5C21Q36316717-5494F43B-88F9-48CC-BD0A-D57972A76546Q36610441-67ED5D0B-2873-49B0-ACB4-DF5B30D99DBDQ36695083-11481A11-757F-4EB0-BCD1-E57002BA023AQ36788436-7286EF82-4D7D-4AB3-8BA8-E5A14A8B9AFFQ37341155-23C72A8B-C48B-49A8-B71B-1AAB4C2F3B87Q37513908-B6DEB78D-7507-4D78-B7EC-E696C63CB6A7Q38693919-EBDC4854-A307-4976-ABD4-EB678D79B6CEQ38707400-C107B0B7-58A0-4454-82C7-4EE335E10A39Q38806782-2F977F72-B519-4A13-B43E-9D4240DBEBEDQ38999820-B1183BF0-FED7-4DF1-93E2-E9A32DFA5AB4Q39639803-11667422-CC71-4C71-B1A4-D29FFF470141Q39710105-93A93C9F-98C2-4DDD-9EA6-80B3AE812AA2Q40153241-F3B80BDC-23CF-42BB-811F-366B16013139Q40698597-E2ED1766-48BF-4AFA-B7DC-C041B7E97295Q41591592-ABBFF0D3-2C2F-4388-8FFE-A770D588535DQ42650614-D9C52BBE-93F9-46D0-BCD1-1209EC3DC10BQ43797701-C71210BD-02D2-4836-8112-B96F243046AEQ44211562-51901573-9333-48C4-ADB3-9E3BE920387DQ45357979-3C268284-E7AC-448B-9F6B-D7594BD42C3FQ45837121-D22260D5-1734-4F14-A57C-F2A712271B8DQ46099008-B25B4DC9-DAF9-498E-93EC-F2BA20A9DA63Q50111382-7AC14A7D-88A8-42B0-984F-AA45053F011BQ54409428-F2C079AC-308C-45BF-95A9-56E53D022CC6Q58760407-023DCE48-D282-42FF-B4D7-CEEC1D8FFA10
P2860
Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Oxaliplatin. A review of its p ...... tential in other malignancies.
@ast
Oxaliplatin. A review of its p ...... tential in other malignancies.
@en
Oxaliplatin. A review of its p ...... tential in other malignancies.
@nl
type
label
Oxaliplatin. A review of its p ...... tential in other malignancies.
@ast
Oxaliplatin. A review of its p ...... tential in other malignancies.
@en
Oxaliplatin. A review of its p ...... tential in other malignancies.
@nl
prefLabel
Oxaliplatin. A review of its p ...... tential in other malignancies.
@ast
Oxaliplatin. A review of its p ...... tential in other malignancies.
@en
Oxaliplatin. A review of its p ...... tential in other malignancies.
@nl
P2093
P1433
P1476
Oxaliplatin. A review of its p ...... tential in other malignancies.
@en
P2093
P304
P356
10.2165/00003495-200060040-00005
P577
2000-10-01T00:00:00Z
P6179
1049451615